Sell Sun Pharma, Buy Aurobindo. Why? AskBQ
#AskBQ is BloombergQuint's daily offering where market experts help investors make the right investment choice — be it in equities, commodities or the derivatives markets.
On Monday's episode, Gaurang Shah of Geojit Financial Services and Kiran Jadhav of Kiran Jadhav and Associates gave their views on Sun Pharma, Dollar Industries, Minda Industries, and many more.
Watch the full conversation here:
Edited excerpts from the conversation:
Ajith Kumar: I bought 100 shares of Sun Pharma at Rs 790 apiece with a one-year-view. Should I hold or sell?
Gaurang Shah: I recommend the investor to sell the stock at current levels or on rallies. Aurobindo Pharma can be a good bet.
Bighnaraj Mishra: Is it the right time to invest in Dollar Industries with a five-year-view?
Kiran Jadhav: I recommend to hold the stock with a stoploss of Rs 440.
Prateek Gattani: Is it the right time to invest in Simplex Infra and Minda Industries with a two-year-view?
Gaurang Shah: I would advise to start investment in both and add on dips.
Satya Subhash: Is it the right time to invest in Meghmani Organics with a two-year-view?
Kiran Jadhav: Yes, the investor can invest with a stoploss of Rs 95 and target of Rs 135.
Akshay Rao: Is it the right time to invest in Ashok Leyland?
Kiran Jadhav: We are quite upbeat on Ashok Leyland and all long positions should have a stoploss of Rs 109, with a target of Rs 124.
Salil Dhawan: I bought 195 shares of IndusInd Bank at Rs 1,311 apiece. Should I add more via SIP?
Gaurang Shah: I suggest that the investor do the SIP, but don't remain focused on one sector. Look at three-four sectors, have one-two stocks in each and go ahead with the SIP plan.
Here's how you can get your queries answered:
- Tweet us your queries using #AskBQ
- WhatsApp us on +91-8291229686
- Call us on 022-45404141
- Email us on askbq@bloombergquint.com
Analysts' Disclosure:
- Gaurang Shah said he does not have any financial interest and does not hold any stocks that were discussed today.
- Kiran Jadhav said he does not have any personal holdings in any of the stocks discussed.
Disclaimer: The commentary on BloombergQuint represents the view of external experts. Investors are advised to consult a certified financial advisor/planner when making any investments. No views shared on a BloombergQuint program or story or conversation should be construed as personal advice.
Quintillion Business Media Pvt. (BloombergQuint) is not responsible for any risk or loss that might occur as a result of using this information in any way, regardless of your interpretation of the advice.
BloombergQuint's digital and social media platforms provide views of only SEBI registered investment advisors/analysts.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
